Colistin, mechanisms and prevalence of resistance

References

• Kasiakou SK, Michalopoulos A, Soteriades ES, et al. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005;49:3136-46
   PubMed Web of Science ®Google Scholar
• Spellberg B, Blaser M, Guidos RJ, et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011;52(Suppl 5):S397-428
   PubMedGoogle Scholar
• Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis 2014;59:88-94
   PubMed Web of Science ®Google Scholar
• Li J, Rayner CR, Nation RL, et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006;50:2946-50
   PubMed Web of Science ®Google Scholar
• Hsueh PR, Tseng SP, Teng LJ, Ho SW. Pan-drug-resistant Pseudomonas aeruginosa causing nosocomial infection at a university hospital in Taiwan. Clin Microbiol Infect 2005;11:670-3
   PubMed Web of Science ®Google Scholar
• Littlewood JM, Koch C, Lambert PA, et al. A ten year review of colomycin. Respir Med 2000;94:632-40
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006;50:1953-8
   PubMed Web of Science ®Google Scholar
• Velkov T, Thompson PE, Nation RL, Li J. Structure–activity relationships of polymyxin antibiotics. J Med Chem 2009;53:1898-916
   Web of Science ®Google Scholar
• Adams MD, Nickel GC, Bajaksouzian S, et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 2009;53:3628-34
   PubMed Web of Science ®Google Scholar
• Bassetti M, Repetto E, Righi E, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008;61:417-20
   PubMed Web of Science ®Google Scholar
• Li J, Nation RL, Milne RW, et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005;25:11-25
   PubMed Web of Science ®Google Scholar
• Rios FG, Luna CM, Maskin B, et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur Respir J 2007;30:307-13
   PubMed Web of Science ®Google Scholar
• Gunderson BW, Ibrahim KH, Hovde LB, et al. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003;47:905-9
   PubMed Web of Science ®Google Scholar
• Falagas ME, Michalopoulos A. Polymyxins: old antibiotics are back. Lancet 2006;367:633-34
   PubMed Web of Science ®Google Scholar
• Brink AJ, Richards GA, Colombo G, et al. Multicomponent antibiotic substances produced by fermentation: implications for regulatory authorities, critically ill patients and generics. Int J Antimicrob Agents 2014;43:1-6
   PubMed Web of Science ®Google Scholar
• Li J, Milne RW, Nation RL, et al. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother 2002;46:3304-7
   PubMed Web of Science ®Google Scholar
• Dhariwal AK, Tullu MS. Colistin: re-emergence of the ‘forgotten' antimicrobial agent. J Postgrad Med 2013;59:208-15
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Landersdorfer CB, Zhang J, et al. Pharmacokinetics and pharmacodynamics of ‘old' polymyxins: what is new? Diagn Microbiol Infect Dis 2012;74:213-23
   PubMed Web of Science ®Google Scholar
• Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601
   PubMed Web of Science ®Google Scholar
• Li J, Milne RW, Nation RL, et al. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother 2003;47:1364-70
   PubMed Web of Science ®Google Scholar
• Li J, Milne RW, Nation RL, et al. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004;53:837-40
   PubMed Web of Science ®Google Scholar
• Beveridge EG, Martin AJ. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol Chemother 1967;29:125-35
   PubMed Web of Science ®Google Scholar
• Schwartz BS, Warren MR, Barkley FA, Landis L. Microbiological and pharmacological studies of colistin sulfate and sodium colistinmethanesulfonate. Antibiotics Annual 1959;7:41-60
   PubMedGoogle Scholar
• Boisson M, Gregoire N, Couet W, Mimoz O. Colistin in critically ill patients. Minerva Anestesiologica 2013;79:200-8
   PubMed Web of Science ®Google Scholar
• Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin Microbiol Rev 2008;21:449-65
   PubMed Web of Science ®Google Scholar
• Vaara M, Vaara T. Structure–activity studies on novel polymyxin derivatives that carry only three positive charges. Peptides 2010;31:2318-21
   PubMed Web of Science ®Google Scholar
• Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011;55:3284-94
   PubMed Web of Science ®Google Scholar
• Ziaka M, Markantonis SL, Fousteri M, et al. Combined intravenous and intraventricular administration of colistin methanesulfonate in critically ill patients with central nervous system infection. Antimicrob Agents Chemother 2013;57:1938-40
   PubMed Web of Science ®Google Scholar
• Froman J, Gross L, Curatola S. Serum and urine levels following parenteral administration of sodium colistimethate to normal individuals. J Urol 1970;103:210-14
   PubMed Web of Science ®Google Scholar
• Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Therapeut 2008;30:143-51
   PubMed Web of Science ®Google Scholar
• Wertheim H, Van Nguyen K, Hara GL, et al. Global survey of polymyxin use: a call for international guidelines. J Global Antimicrob Resist 2013;1:131-4
   PubMed Web of Science ®Google Scholar
• Mohamed AF, Karaiskos I, Plachouras D, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 2012;56:4241-9
   PubMed Web of Science ®Google Scholar
• Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009;53:3430-6
   PubMed Web of Science ®Google Scholar
• Couet W, Gregoire N, Marchand S, Mimoz O. Colistin pharmacokinetics: the fog is lifting. Clin Microbiol Infect 2012;18:30-9
   PubMed Web of Science ®Google Scholar
• Li J, Turnidge J, Milne R, et al. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001;45:781-5
   PubMed Web of Science ®Google Scholar
• Luque S, Grau S, Valle M, et al. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2013;42:178-81
   PubMed Web of Science ®Google Scholar
• MacKay DN, Kaye D. Serum concentrations of colistin in patients with normal and impaired renal function. N Engl J Med 1964;270:394-97
   PubMed Web of Science ®Google Scholar
• Curitis JR, Eastwood JB. Colistin sulphomethate sodium administration in the presence of severe renal failure and during haemodialysis and peritoneal dialysis. Br Med J 1968;1:484-5
   PubMed Web of Science ®Google Scholar
• Michalopoulos AS, Falagas ME. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care 2011;1:1-6
   Google Scholar
• Tan T, Ng SY. The in-vitro activity of colistin in gram-negative bacteria. Singapore Med J 2006;47:621-4
   PubMedGoogle Scholar
• Renard L, Sanders P, Laurentie M. [Pharmacokinetics of colistin sulfate administered by intravenous and intramuscular routes in the calf]. Ann Vet Res 1990;22:387-94
   Google Scholar
• Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-41
   PubMed Web of Science ®Google Scholar
• Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006–09). J Antimicrob Chemother 2011;66:2070-4
   PubMed Web of Science ®Google Scholar
• Vaara M. Polymyxins and their novel derivatives. Curr Opin Microbiol 2010;13:574-81
   PubMed Web of Science ®Google Scholar
• Muyembe T, Vandepitte J, Desmyter J. Natural colistin resistance in Edwardsiella tarda. Antimicrob Agents Chemother 1973;4:521-4
   PubMed Web of Science ®Google Scholar
• Shimizu S, Iyobe S, Mitsuhashi S. Inducible high resistance to colistin in Proteus strains. Antimicrob Agents Chemother 1977;12:1-3
   PubMed Web of Science ®Google Scholar
• Boisson M, Gregoire N, Couet W, Mimoz O. Colistin in critically ill patients. Minerva Anestesiologica 2013;79:200-8
   PubMed Web of Science ®Google Scholar
• Fosse T, Giraud-Morin C, Madinier I. Induced colistin resistance as an identifying marker for Aeromonas phenospecies groups. Lett Applied Microbiol 2003;36:25-9
   PubMed Web of Science ®Google Scholar
• Yahav D, Farbman L, Leibovici L, Paul M. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect 2012;18:18-29
   PubMed Web of Science ®Google Scholar
• Lee CS, Doi Y. Therapy of infections due to carbapenem-resistant gram-negative pathogens. Infect Chemother 2014;46:149-64
   PubMedGoogle Scholar
• Vidaillac C, Benichou L, Duval RE. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 2012;56:4856-61
   PubMed Web of Science ®Google Scholar
• Beceiro A, Moreno A, Fernandez N, et al. Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii. Antimicrob Agents Chemother 2014;58:518-26
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis PI, Matthaiou DK. Resistance to polymyxins: mechanisms, frequency and treatment options. Drug Resist Updates 2010;13:132-8
   PubMed Web of Science ®Google Scholar
• Mendes CA, Burdmann EA. [Polymyxins – review with emphasis on nephrotoxicity]. Revista da Associacao Medica Brasileira 2009;55:752-9
   PubMed Web of Science ®Google Scholar
• Moffatt JH, Harper M, Harrison P, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 2010;54:4971-7
   PubMed Web of Science ®Google Scholar
• Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999;33:960-7
   PubMed Web of Science ®Google Scholar
• Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001–2004). Clin Microbiol Infect 2006;12:315-21
   PubMed Web of Science ®Google Scholar
• Martis N, Leroy S, Blanc V. Colistin in multi-drug resistant Pseudomonas aeruginosa blood-stream infections: a narrative review for the clinician. J Infect 2014;69:1-12
   PubMed Web of Science ®Google Scholar
• Sampson TR, Liu X, Schroeder MR, et al. Rapid killing of Acinetobacter baumannii by polymyxins is mediated by a hydroxyl radical death pathway. Antimicrob Agents Chemother 2012;56:5642-9
   PubMed Web of Science ®Google Scholar
• Park YK, Choi JY, Shin D, Ko KS. Correlation between overexpression and amino acid substitution of the PmrAB locus and colistin resistance in Acinetobacter baumannii. Int J Antimicrob Agents 2011;37:525-30
   PubMed Web of Science ®Google Scholar
• Johansen HK, Moskowitz SM, Ciofu O, et al. Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J Cystic Fibrosis 2008;7:391-7
   PubMed Web of Science ®Google Scholar
• Kim Y, Bae IK, Lee H, et al. In vivo emergence of colistin resistance in Acinetobacter baumannii clinical isolates of sequence type 357 during colistin treatment. Diagn Microbiol Infect Dis 2014;79:362-6
   PubMed Web of Science ®Google Scholar
• Ito-Kagawa M, Koyama Y. Selective cleavage of a peptide antibiotic, colistin by colistinase. J Antibiotics 1980;33:1551-5
   PubMed Web of Science ®Google Scholar
• Lopez-Rojas R, Dominguez-Herrera J, McConnell MJ, et al. Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii. J Infect Dis 2011;203:545-8
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 2007;60:1206-15
   PubMed Web of Science ®Google Scholar
• Snitkin ES, Zelazny AM, Gupta J, et al. Genomic insights into the fate of colistin resistance and Acinetobacter baumannii during patient treatment. Genome Res 2013;23:1155-62
   PubMed Web of Science ®Google Scholar
• Kim SY, Choi HJ, Ko KS. Differential expression of two-component systems, pmrAB and phoPQ, with different growth phases of Klebsiella pneumoniae in the presence or absence of colistin. Curr Microbiol 2014;69:37-41
   PubMed Web of Science ®Google Scholar
• Beceiro A, Llobet E, Aranda J, et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother 2011;55:3370-9
   PubMed Web of Science ®Google Scholar
• Pamp SJ, Gjermansen M, Johansen HK, Tolker-Nielsen T. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol Microbiol 2008;68:223-40
   PubMed Web of Science ®Google Scholar
• Peter H, Berggrav K, Thomas P, et al. Direct detection and genotyping of Klebsiella pneumoniae carbapenemases from urine by use of a new DNA microarray test. J Clin Microbiol 2012;50:3990-8
   PubMed Web of Science ®Google Scholar
• Moskowitz SM, Garber E, Chen Y, et al. Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia. J Antimicrob Chemother 2010;65:1416-23
   PubMed Web of Science ®Google Scholar
• Moffatt JH, Harper M, Adler B, et al. Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents Chemother 2011;55:3022-4
   PubMed Web of Science ®Google Scholar
• Lee K, Yong D, Jeong SH, Chong Y. Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens. Yonsei Med J 2011;52:879-91
   PubMed Web of Science ®Google Scholar
• Lean SS, Suhaili Z, Ismail S, et al. Prevalence and genetic characterization of carbapenem- and polymyxin-resistant acinetobacter baumannii isolated from a tertiary hospital in Terengganu, Malaysia. ISRN microbiology 2014:1-9
   Google Scholar
• Adams MD, Goglin K, Molyneaux N, et al. Comparative genome sequence analysis of multidrug-resistant Acinetobacter baumannii. J Bacteriol 2008;190:8053-64
   PubMed Web of Science ®Google Scholar
• Haagensen JA, Klausen M, Ernst RK, et al. Differentiation and distribution of colistin- and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms. J Bacteriol 2007;189:28-37
   PubMed Web of Science ®Google Scholar
• Lee JY, Na IY, Park YK, Ko KS. Genomic variations between colistin-susceptible and -resistant Pseudomonas aeruginosa clinical isolates and their effects on colistin resistance. J Antimicrob Chemother 2014;69:1248-56
   PubMed Web of Science ®Google Scholar
• Lee JY, Ko KS. Mutations and expression of PmrAB and PhoPQ related with colistin resistance in Pseudomonas aeruginosa clinical isolates. Diagn Microbiol Infect Dis 2014;78:271-6
   PubMed Web of Science ®Google Scholar
• McPhee JB, Lewenza S, Hancock RE. Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa. Mol Microbiol 2003;50:205-17
   PubMed Web of Science ®Google Scholar
• Ly NS, Yang J, Bulitta JB, Tsuji BT. Impact of two-component regulatory systems PhoP-PhoQ and PmrA-PmrB on colistin pharmacodynamics in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2012;56:3453-6
   PubMed Web of Science ®Google Scholar
• Gunn JS, Lim KB, Krueger J, et al. PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. Mol Microbiol 1998;27:1171-82
   PubMed Web of Science ®Google Scholar
• Roland KL, Martin LE, Esther CR, Spitznagel JK. Spontaneous pmrA mutants of Salmonella typhimurium LT2 define a new two-component regulatory system with a possible role in virulence. J Bacteriol 1993;175:4154-64
   PubMed Web of Science ®Google Scholar
• Groisman EA, Kayser J, Soncini FC. Regulation of polymyxin resistance and adaptation to low-Mg2+ environments. J Bacteriol 1997;179:7040-5
   PubMed Web of Science ®Google Scholar
• Cannatelli A, Giani T, D'Andrea MM, et al. MgrB inactivation is a common mechanism of colistin resistance in KPC-producing klebsiella pneumoniae of clinical origin. Antimicrob Agents Chemother 2014;58:5696-703
   PubMed Web of Science ®Google Scholar
• Cannatelli A, D'Andrea MM, Giani T, et al. In vivo emergence of colistin resistance in Klebsiella pneumoniae producing KPC-type carbapenemases mediated by insertional inactivation of the PhoQ/PhoP mgrB regulator. Antimicrob Agents Chemother 2013;57:5521-6
   PubMed Web of Science ®Google Scholar
• Hawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance in acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 2008;52:351-2
   PubMed Web of Science ®Google Scholar
• Deris ZZ, Heidi HY, Davis K, et al. The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2012;56:5103-12
   PubMed Web of Science ®Google Scholar
• Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 2008;14:816-27
   PubMed Web of Science ®Google Scholar
• Gu WJ, Wang F, Tang L, et al. Colistin for the treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: a systematic review and meta-analysis. Int J Antimicrob Agents 2014;44:477-85
   Google Scholar
• Naghmouchi K, Baah J, Hober D, et al. Synergistic effect between colistin and bacteriocins in controlling Gram-negative pathogens and their potential to reduce antibiotic toxicity in mammalian epithelial cells. Antimicrob Agents Chemother 2013;57:2719-25
   PubMed Web of Science ®Google Scholar
• Lopez-Fabal F, Culebras E, Bonilla I, et al. [In vitro activities of colistin combinations against Pseudomonas aeruginosa isolated from the intensive care unit]. Revista Espanola de Quimioterapia 2008;21:189-93
   PubMed Web of Science ®Google Scholar
• Aoki N, Tateda K, Kikuchi Y, et al. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 2009;63:534-42
   PubMed Web of Science ®Google Scholar
• Tascini C, Gemignani G, Palumbo F, et al. Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant Pseudomonas aeruginosa diabetic foot infections with or without osteomyelitis. J Chemother (Florence, Italy) 2006;18:648-51
   PubMed Web of Science ®Google Scholar
• Nagaoka R, Ikawa K, Onodera M, et al. In vitro combined effects of double antibacterial drugs against multidrug-resistant Pseudomonas aeruginosa isolates: comparison among combinations of colistin, arbekacin, aztreonam, rifampicin and piperacillin. Jpn J Antibiot 2014;67:167-74
   PubMedGoogle Scholar
• Tascini C, Tagliaferri E, Giani T, et al. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2013;57:3990-3
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Amaya-Villar R, Gutierrez-Pizarraya A, et al. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Chemother 2013;59:225-31
   PubMed Web of Science ®Google Scholar
• Kalin G, Alp E, Akin A, et al. Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Infection 2014;42:37-42
   PubMed Web of Science ®Google Scholar
• Batirel A, Balkan II, Karabay O, et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 2014;33:1311-22
   PubMed Web of Science ®Google Scholar
• Lora-Tamayo J, Murillo O, Bergen PJ, et al. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model. J Antimicrob Chemother 2014;69:2434-42
   PubMed Web of Science ®Google Scholar
• Hachem RY, Chemaly RF, Ahmar CA, et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother 2007;51:1905-11
   PubMed Web of Science ®Google Scholar
• Koomanachai P, Landersdorfer CB, Chen G, et al. Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 2014;58:440-6
   PubMed Web of Science ®Google Scholar
• Sinirtas M, Akalin H, Gedikoglu S. Investigation of colistin sensitivity via three different methods in Acinetobacter baumannii isolates with multiple antibiotic resistance. Int J Infect Dis 2009;13:e217-20
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006;10:R27
   PubMed Web of Science ®Google Scholar
• Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011;53:879-84
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis P, Kasiakou SK, et al. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin–meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect 2006;12:1227-30
   PubMed Web of Science ®Google Scholar
• Balkan II, Dogan M, Durdu B, et al. Colistin nephrotoxicity increases with age. Scand J Infect Dis 2014;46:678-85
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res 2006;4:138-46
   PubMedGoogle Scholar
• Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis 2014;59:88-94
   Google Scholar
• Yau W, Owen RJ, Poudyal A, et al. Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J Infect 2009;58:138-44
   PubMed Web of Science ®Google Scholar
• Napier BA, Band V, Burd EM, Weiss DS. Colistin heteroresistance in Enterobacter cloacae is associated with cross-resistance to the host antimicrobial lysozyme. Antimicrob Agents Chemother 2014;58:5594-7
   PubMed Web of Science ®Google Scholar
• Keen EF III, Robinson BJ, Hospenthal DR, et al. Prevalence of multidrug-resistant organisms recovered at a military burn center. Burns 2010;36:819-25
   PubMed Web of Science ®Google Scholar
• Landman D, Bratu S, Alam M, Quale J. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J Antimicrob Chemother 2005;55:954-57
   PubMed Web of Science ®Google Scholar
• Walkty A, DeCorby M, Nichol K, et al. In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007–2008. Antimicrob Agents Chemother 2009;53:4924-6
   PubMed Web of Science ®Google Scholar
• Rodriguez CH, Bombicino K, Granados G, et al. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microbiol Infect Dis 2009;65:188-91
   PubMed Web of Science ®Google Scholar
• Ahmed NH, Baba K, Clay C, et al. In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa. BMC Res Notes 2012;5:215
   PubMedGoogle Scholar
• Iroha EO, Kesah CN, Egri-Okwaji MT, Odugbemi TO. Bacterial eye infection in neonates, a prospective study in a neonatal unit. West African J Med 1998;17:168-72
   PubMedGoogle Scholar
• Mezghani Maalej S, Rekik Meziou M, Mahjoubi F, Hammami A. Epidemiological study of Enterobacteriaceae resistance to colistin in Sfax (Tunisia). Medecine et Maladies Infectieuses 2012;42:256-63
   PubMed Web of Science ®Google Scholar
• Igumbor E, Gwanzura L, Chirara M, et al. Antibiotic sensitivity and plasmid profiles of Pseudomonas aeruginosa. Central African J Med 2000;46:296-300
   PubMedGoogle Scholar
• Pitt TL, Sparrow M, Warner M, Stefanidou M. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 2003;58:794-6
   PubMed Web of Science ®Google Scholar
• Arroyo LA, Garcia-Curiel A, Pachon-Ibanez ME, et al. Reliability of the E-test method for detection of colistin resistance in clinical isolates of Acinetobacter baumannii. J Clin Microbiol 2005;43:903-5
   PubMed Web of Science ®Google Scholar
• Miftode E, Dorneanu O, Leca D, et al. [Antimicrobial resistance profile of E. coli and Klebsiella spp. from urine in the Infectious Diseases Hospital Iasi]. Revista Medico-Chirurgicala a Societatii de Medici si Naturalisti din Iasi 2008;112:478-82
   PubMedGoogle Scholar
• Capone A, Giannella M, Fortini D, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 2013;19:E23-30
   PubMed Web of Science ®Google Scholar
• Mammina C, Bonura C, Di Bernardo F, et al. Ongoing spread of colistin-resistant Klebsiella pneumoniae in different wards of an acute general hospital, Italy, June to December 2011. Euro Surveillance: European Communicable Disease Bulletin 2012;17:1-4
   Google Scholar
• Giamarellos-Bourboulis E, Sambatakou H, Galani I, Giamarellou H. In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J Chemother 2003;15:235-8
   PubMed Web of Science ®Google Scholar
• Kontopidou F, Plachouras D, Papadomichelakis E, et al. Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients. Clin Microbiol Infect 2011;17:E9-11
   PubMed Web of Science ®Google Scholar
• Neonakis IK, Samonis G, Messaritakis H, et al. Resistance status and evolution trends of Klebsiella pneumoniae isolates in a university hospital in Greece: ineffectiveness of carbapenems and increasing resistance to colistin. Chemotherapy 2010;56:448-52
   PubMed Web of Science ®Google Scholar
• Kontopoulou K, Protonotariou E, Vasilakos K, et al. Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 beta-lactamase resistant to colistin. J Hosp Infect 2010;76:70-3
   PubMed Web of Science ®Google Scholar
• Toth A, Damjanova I, Puskas E, et al. Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary. Eur J Clin Microbiol Infect Dis 2010;29:765-9
   PubMed Web of Science ®Google Scholar
• Kempf I, Fleury MA, Drider D, et al. What do we know about resistance to colistin in Enterobacteriaceae in avian and pig production in Europe? Int J Antimicrob Agents 2013;42:379-83
   PubMed Web of Science ®Google Scholar
• Turnidge J, Bell J, Jones R. Emergence of colistin-resistant Klebsiella spp., and Enterobacter spp. in the Asia-Pacific (APAC) region: a SENTRY antimicrobial surveillance program report (2006). Conf Antimicrob Agents Chemother American Society for Microbiology, Washington, DC; 2007;2007
   Google Scholar
• Chen S, Hu F, Zhang X, et al. Independent emergence of colistin-resistant Enterobacteriaceae clinical isolates without colistin treatment. J Clin Microbiol 2011;49:4022-3
   PubMed Web of Science ®Google Scholar
• Lin L, Ling BD, Li XZ. Distribution of the multidrug efflux pump genes, adeABC, adeDE and adeIJK, and class 1 integron genes in multiple-antimicrobial-resistant clinical isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus complex. Int J Antimicrob Agents 2009;33:27-32
   PubMed Web of Science ®Google Scholar
• Vakili B, Fazeli H, Shoaei P, et al. Detection of colistin sensitivity in clinical isolates of Acinetobacter baumannii in Iran. J Res Med Sci 2014;19(Suppl 1):S67-70
   Google Scholar
• Bahador A, Taheri M, Pourakbari B, et al. Emergence of rifampicin, tigecycline, and colistin-resistant Acinetobacter baumannii in Iran; spreading of MDR strains of novel international clone variants. Microb Drug Resist (Larchmont, NY) 2013;19:397-406
   PubMed Web of Science ®Google Scholar
• Ko KS, Suh JY, Kwon KT, et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother 2007;60:1163-7
   PubMed Web of Science ®Google Scholar
• Park YK, Jung SI, Park KH, et al. Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea. Diagn Microbiol Infect Dis 2009;64:43-51
   PubMed Web of Science ®Google Scholar
• Suh JY, Son JS, Chung DR, et al. Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea. Antimicrob Agents Chemother 2010;54:560-2
   PubMed Web of Science ®Google Scholar
• Ayan M, Durmaz R, Aktas E, Durmaz B. Bacteriological, clinical and epidemiological characteristics of hospital-acquired Acinetobacter baumannii infection in a teaching hospital. J Hosp Infect 2003;54:39-45
   PubMed Web of Science ®Google Scholar
• Timurkaynak F, Can F, Azap OK, et al. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 2006;27:224-8
   PubMed Web of Science ®Google Scholar
• Dizbay M, Altuncekic A, Sezer BE, et al. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia. Int J Antimicrob Agents 2008;32:29-32
   PubMed Web of Science ®Google Scholar
• Eser OK, Ergin A, Hascelik G. [Antimicrobial resistance and existence of metallo-beta-lactamase in Acinetobacter species isolated from adult patients]. Mikrobiyoloji Bulteni 2009;43:383-90
   PubMed Web of Science ®Google Scholar
• Tribuddharat C, Tiensasitorn C, Techachaiwiwat W, et al. In vitro activity of polymyxin B and polymyxin E against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii. J Infect Dis Antimicrob Agents 2003;20:135-7
   Google Scholar
• Tunyapanit W, Pruekprasert P, Laoprasopwattana K, Chelae S. In vitro activity of colistin against multidrug-resistant Pseudomonas aeruginosa isolates from patients in Songklanagarind Hospital, Thailand. Southeast Asian J Trop Med Publ Health 2013;44:273-80
   PubMed Web of Science ®Google Scholar
• Punpanich W, Tantichattanon W, Wongwatcharapaiboon S, Treeratweeraphong V. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria. J Med Assoc Thailand 2008;91(Suppl 3):S21-7
   Google Scholar
• Mohanty S, Maurya V, Gaind R, Deb M. Phenotypic characterization and colistin susceptibilities of carbapenem-resistant of Pseudomonas aeruginosa and Acinetobacter spp. J Infection Developing Countries 2013;7:880-7
   PubMed Web of Science ®Google Scholar
• Varaiya A, Kulkarni M, Bhalekar P, Dogra J. Incidence of metallo-beta-lactamase-producing Pseudomonas aeruginosa in diabetes and cancer patients. Ind J Pathol Microbiol 2008;51:200-3
   PubMed Web of Science ®Google Scholar
• Manoharan A, Chatterjee S, Mathai D. Detection and characterization of metallo beta lactamases producing Pseudomonas aeruginosa. Ind J Med Microbiol 2010;28:241-4
   PubMed Web of Science ®Google Scholar
• Taneja N, Singh G, Singh M, Sharma M. Emergence of tigecycline & colistin resistant Acinetobacter baumanii in patients with complicated urinary tract infections in north India. Ind J Med Res 2011;133:681-4
   PubMed Web of Science ®Google Scholar
• Hawley JS, Murray CK, Griffith ME, et al. Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel. Antimicrob Agents Chemother 2007;51:376-8
   PubMed Web of Science ®Google Scholar
• Hussein K, Sprecher H, Mashiach T, et al. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect Contr Hosp Epidemiol 2009;30:666-71
   PubMed Web of Science ®Google Scholar
• Zhao M, Cao Y-R, Guo B-N, et al. LC-MS/MS determination of colistin in Mueller-Hinton broth for in vitro pharmacodynamic studies. J Antibiot 2014;67:825-9
   Google Scholar